The global Small Lymphocytic Lymphoma Treatment market has significantly grown over the past few years and is expected to register rapid growth. Revenue.
Rafael (NYSE:RFL – Get Rating) posted its earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, reports. Rafael had a negative net margin of 2,813.93% and a negative return on equity of 14.63%. The company had revenue of $0.07 million during the quarter. Rafael Stock Performance Shares of Rafael stock […]
Rafael (NYSE:RFL – Get Rating) and Getty Realty (NYSE:GTY – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Risk and Volatility Rafael has a beta of 1.66, suggesting […]
Rafael Holdings, Inc. (NYSE:RFL – Get Rating)’s stock price traded up 1.6% during mid-day trading on Monday . The stock traded as high as $1.95 and last traded at $1.93. 8,592 shares changed hands during trading, a decline of 86% from the average session volume of 59,963 shares. The stock had previously closed at $1.90. […]
/PRNewswire/ DelveInsight s Soft Tissue Sarcoma Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline.